XHKG
1302
Market cap734mUSD
Oct 09, Last price
1.35HKD
1D
3.05%
1Q
-3.57%
Jan 2017
-27.42%
IPO
440.00%
Name
LifeTech Scientific Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. The company’s products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, HeartR, and Konar-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; Futhrough endovascular needle systems; delivery systems, such as Fustar steerable and SteerEase introducers; Zoetrack guidewire; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; HearTone implantable cardiac pacing system; and SeQure snare systems, as well as pacemakers. It also involved in the biomedical research and development; properties leasing business; and developing, manufacturing, and trading of medical devices, as well as offers technical, consulting, and technology services. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, China.
Key people
Yuehui Xie
Executive Chairman of the Board, Chief Executive Officer · since 2015
Jiangbo Han
Chief Operating Officer · since 2014
Deyuan Zhang
Chief Scientist · since 2019
Jianxiong Joseph Liu
Chief Financial Officer, Executive Director, Company Secretary · since 2015
Mark Cibuzar
Overseas Sales Director
Sajeevan Manikkoth
India Sales Director
Guowei Zhan
Domestic Sales Director
Feng Fu
Non-Executive Director · since 2019
Feng Jiang
Non-Executive Director · since 2014
Hsien-Tse Liang
Non-Executive Independent Director · since 2011
Wansong Wang
Non-Executive Independent Director · since 2016
Luming Zhou
Independent Non-Executive Director · since 2014
Headquarters & legal address
Box 309 Ugland House
Grand Cayman KY1-1104
KY
Grand Cayman KY1-1104
KY
Address
阿格兰德大厦309号邮政信箱
大开曼岛 KY1-1104
KY
大开曼岛 KY1-1104
KY
Other language
LifeTech Scientific Corporation
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||